Comparison of caspofungin and amphotericin B for invasive candidiasis

New England Journal of Medicine

Volumn 347, Issue 25, 2002, Pages 2020-2029

  Mora Duarte, Jorge ^a   Betts, Robert ^b   Rotstein, Coleman ^c   Lopes Colombo, Arnaldo ^d   Thompson Moya, Luis ^e   Smietana, Juanita ^f   Lupinacci, Robert ^f   Sable, Carole ^f   Kartsonis, Nicholas ^f   Perfect, John ^g  

^a Hosp Mexico   (Costa Rica)

^b UNIVERSITY OF ROCHESTER   (United States)

^c MCMASTER UNIVERSITY   (Canada)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^e CLÍNICA SANTA MARÍA   (Chile)

^f MERCK RESEARCH LABORATORIES   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMPHOTERICIN B; ANTIBIOTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CASPOFUNGIN; CREATININE; CYCLOSPORIN; FLUCONAZOLE; HEMOGLOBIN; IMMUNOSUPPRESSIVE AGENT; POTASSIUM; PYRROLE; RIFAMPICIN; RITONAVIR;

ABDOMINAL ABSCESS; ADOLESCENT; ADULT; AGED; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDIASIS; CHILL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG INFUSION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEVER; FOLLOW UP; FUNGAL CELL CULTURE; HUMAN; HYPERTENSION; HYPOKALEMIA; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; PERITONITIS; PHLEBITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SCORING SYSTEM; TACHYCARDIA; TACHYPNEA; THROMBOPHLEBITIS; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMPHOTERICIN B; ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTIFUNGAL; APACHE; CANDIDA; CANDIDIASIS; FEMALE; FUNGEMIA; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEUTROPENIA; PEPTIDES; PEPTIDES, CYCLIC; RECURRENCE;

EID: 0037137576     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa021585     Document Type: Article

References (32)

1. Meunier F. Candidiasis. Eur J Clin Microbiol Infect Dis 1989;8:438-47.
2. Bodey GP. Hematogenous and major organ candidiasis. In: Bodey GP, ed. Candidiasis: Pathogenesis, Diagnosis, and Treatment. 2nd Ed. New York: Raven Press, 1992:279-329.
3. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 Years of clinical experience. Rev Infect Dis 1990;12:308-29.
4. Anaissie EJ, Vartivarian SE, Abi-Said D, et al. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: A matched cohort study. Am J Med 1996;101:170-6.
5. Anaissie EJ, Darouiche RO, Abi-Said D, et al. Management of invasive candidal infections: Results of a prospective, randomized multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996;23:964-72.
6. Van't Wout JW, Mattie H, van Furth R. A prospective study of the efficacy of fluconazole (UK-49,858) against deep-seated fungal infections. J Antimicrob Chemother 1988;21:665-72.
7. Kujath P, Lerch K. Secondary mycosis in surgery: Treatment with fluconazole. Infection 1989;17:111-7.
8. Nolla-Salas J, Leon C, Torres-Rodriquez JM, Martin E, Sitges-Serra A. Treatment of candidemia in critically ill surgical patients with intravenous fluconazole. Clin Infect Dis 1992;14:952-4.
9. Graninger W, Presteril E, Schneeweiss B, Teleky B, Georgopoulos A. Treatment of Candida albicans fungaemia with fluconazole. J Infect 1993;26:133-46.
10. Ikemoto H. A clinical study of fluconazole for the treatment of deep mycoses. Diagn Microbiol Infect Dis 1989;12:Suppl:239S-247S.
11. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994;331:1325-30.
12. Phillips P, Shafran S, Garber G, et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Eur J Clin Microbiol Infect Dis 1997;16:337-45.
13. Nguyen MH, Peacock JE, Tanner DC, et al. Therapeutic approaches in patients with candidemia: Evaluation in a multicenter, prospective, observational study. Arch Intern Med 1995;155:2429-35.
14. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995;39:1-8.
15. Pfaller MA, Jones RN, Doern GV, et al. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. Antimicrob Agents Chemother 2000;44:747-51.
16. Yamamura DL, Rotstein C, Nicolle LE, Ioannou S. Candidemia at selected Canadian sites: Results from the Fungal Disease Registry, 1992-1994. CMAJ 1999;160:493-9.
17. Kao AS, Brandt ME, Pruitt WR, et al. The epidemiology of candidemia in two United States cities: Results of a population-based active surveillance. Clin Infect Dis 1999;29:1164-70.
18. Pfaller MA, Jones RN, Doern GV, et al. International surveillance of blood stream infections due to Candida species in the European SENTRY program: Species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. Diagn Microbiol Infect Dis 1999;35:19-25.
19. Bartizal K, Gill CJ, Abruzzo GK, et al. In vitro preclinical evaluation with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother 1997;41:2326-32.
20. Abruzzo GK, Flattery AM, Gill CJ, et al. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): Efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother 1997;41:2333-8.
21. Vazquez JA, Lynch M, Boikov D, Sobel JD. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-sensitive and azoleresistant Candida species. Antimicrob Agents Chemother 1997;41:1612-4.
22. Nelson PW, Lozano-Chiu M, Rex JH. In vitro growth-inhibitory activity of pneumocandins L-733,560 and L-743-872 against putatively amphotericin B- and fluconazole-resistant Candida isolates: Influence of assay conditions. J Med Vet Mycol 1997;35:285-7.
23. Martinez-Suarez JV, Rodriquez-Tudela JL. In vitro activities of semisynthetic pneumocandin L-733,560 against fluconazole-resistant and -susceptible Candida albicans isolates. Antimicrob Agents Chemother 1996;40:1277-9.
24. Barchiesi F, Schimizzi AM, Fothergill AW, Scalise G, Rinaldi MG. In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species. Eur J Clin Microbiol Infect Dis 1999;18:302-4.
25. Bachman SP, Pera S, Kirkpatrick WR, Patterson TF, Lopez-Ribot JL. In vitro activity of Cancidas (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. In: Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 17-20, 2000. Washington, D.C.: American Society for Microbiology, 2000:352. abstract.
26. Sable CA, Nguyen B-Y, Chodakewitz JA, Di Nubile MJ. Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transpl Infect Dis 2002;4:25-30.
27. Villanueva A, Arathoon EG, Gotuzzo E, Berman RS, DiNubile MJ, Sable CA. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001;33:1529-35.
28. Arathoon EG, Gotuzzo E, Noriega LM, Berman RS, DiNubile MJ, Sable CA. A randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiasis. Antimicrob Agents Chemother 2002;46:451-7.
29. Villanueva A, Gotuzzo E, Arathoon E, et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002;113:294-9.
30. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002;34:7-14.
31. Colombo AL, Nucci M, Salomao R, et al. High rate of non-albicans candidemia in Brazilian tertiary care hospitals. Diagn Microbiol Infect Dis 1999;34:281-6.
32. Nucci M, Santos LM, Ferradosa AS, Colombo AL. Epidemiology of candidemia due to C. parapsilosis in tertiary care hospitals in Brazil. In: Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, December 16-19, 2001. Washington, D.C.: American Society for Microbiology, 2001:393. abstract.